Completed
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
NCT01188278
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +3 more
- Locations
-
Not specified